Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) Net Income towards Common Stockholders (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Net Income towards Common Stockholders for 11 consecutive years, with $26806.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Income towards Common Stockholders rose 100.79% year-over-year to $26806.0, compared with a TTM value of -$8.6 million through Sep 2025, down 273.44%, and an annual FY2024 reading of $3.6 million, up 127.29% over the prior year.
  • Net Income towards Common Stockholders was $26806.0 for Q3 2025 at Kiora Pharmaceuticals, up from -$2.2 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $13.5 million in Q1 2024 and bottomed at -$14.4 million in Q4 2021.
  • Average Net Income towards Common Stockholders over 5 years is -$2.1 million, with a median of -$2.2 million recorded in 2024.
  • The sharpest move saw Net Income towards Common Stockholders plummeted 5345.16% in 2022, then surged 801.91% in 2024.
  • Year by year, Net Income towards Common Stockholders stood at -$14.4 million in 2021, then surged by 74.27% to -$3.7 million in 2022, then grew by 22.42% to -$2.9 million in 2023, then plummeted by 48.23% to -$4.3 million in 2024, then surged by 100.63% to $26806.0 in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for KPRX at $26806.0 in Q3 2025, -$2.2 million in Q2 2025, and -$2.2 million in Q1 2025.